Abstract
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date.
Reference44 articles.
1. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics;Twomey;AAPS J.,2021
2. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma;Lipson;Clin. Cancer Res.,2011
3. Farkona, S., Diamandis, E.P., and Blasutig, I.M. (2016). Cancer Immunotherapy: The Beginning of the End of Cancer?. BMC Med., 14.
4. BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update;Reig;J. Hepatol.,2022
5. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies;Brar;JCO Oncol. Pract.,2022
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献